Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 31, 2007 Brian Gorman	Merck's Special Interest Merck is likely to succeed in getting states to mandate HPV vaccination. Still, investors shouldn't necessarily bet everything on Gardasil.
The Motley Fool April 4, 2007 Brian Lawler	GlaxoSmithKline Gets Ready for the Vaccine Wars British pharmaceutical powerhouse GlaxoSmithKline submits a marketing application to the FDA for its HPV vaccine. Investors, take note.
The Motley Fool October 19, 2009 Brian Orelli	The HPV Vaccine Wars of 2010 Merck and GlaxoSmithKline human papillomavirus vaccines were both approved by the Food and Drug Administration for different indications.
The Motley Fool July 20, 2007 Brian Lawler	Glaxo Heats Up the Vaccine Battle GlaxoSmithKline's cervical cancer vaccine gets a positive recommendation in the EU. Sales could begin in early 2008 and will compete with Gardasil, by rival Merck.
The Motley Fool November 13, 2008 Brian Orelli	Merck Could Double Potential Customers Merck's HPV vaccine, Gardasil, which is now recommended for girls and women is also shown to benefit boys and men.
The Motley Fool April 7, 2005 Brian Gorman	Merck Soldiers On The drug company's experimental HPV treatment has significant potential. Investors should not overlook the company's positive developments.
The Motley Fool July 7, 2009 Brian Orelli	Glaxo Missed the Boat The HPV vaccine market is declining before Glaxo can hop aboard.
The Motley Fool June 26, 2008 Brian Orelli	The FDA's Latest Victim Merck fails to get its Gardasil vaccine approved to treat older women.
BusinessWeek November 29, 2004 Kerry Capell	"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome.
The Motley Fool November 6, 2007 Brian Orelli	Getting Vaccinated Alongside Mom Merck presents data supporting use of its HPV vaccine in older women. The drugmaker may have a tough marketing job ahead of it.
The Motley Fool September 25, 2006 Brian Lawler	Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note.
Pharmaceutical Executive May 1, 2006 Joanna Breitstein	Cervical Cancer: Endagered Species Preventive care is more efficient than treating disease after the fact. Now this paradigm takes hold in cancer with new HPV vaccines. Now that the science is in order, Merck and GSK face several important challenges in conditioning the market.
Managed Care September 2006 Thomas Morrow	Remarkable Work Went Into Designing the New HPV Vaccine The recently approved human papillomavirus vaccine is a prime example of how science is beating back the advance of old diseases.
The Motley Fool July 1, 2008 Brian Lawler	FDA News Gives Glaxo a Glimmer of Hope Approval is delayed, but new studies won't be needed for Cervarix.
The Motley Fool December 18, 2007 Brian Lawler	Cervarix Won't Save Glaxo Yet The FDA has another delay for this HPV vaccine. The agency has completed its review, but still has questions.
Scientific American February 2006	To Banish a Cancer Two vaccines that are nearing approval by the Food and Drug Administration in the U.S. have demonstrated in clinical trials that they can prevent infection from the two types of the human papillomavirus (HPV) that account for up to 70 percent of cervical cancers.
The Motley Fool September 10, 2009 Brian Orelli	The Vanishing Vaccine War And it had such potential to be a bloodbath.
BusinessWeek August 27, 2009 Arlene Weintraub	Is Merck Overselling a Cancer Vaccine? Fresh controversies are heating up over the marketing of products to prevent cervical cancer.
The Motley Fool September 28, 2007 Brian Orelli	Free Drugs From Merck Merck plans to donate enough of its Gardasil vaccine to vaccinate one million women, in some of the poorest countries in the world, against the human papilloma virus.
Pharmaceutical Executive February 1, 2007 Beth Herskovits	Brand of the Year A first annual Brand of the Year honor goes to Gardasil, Merck's breakthrough vaccine for human papillomavirus.
The Motley Fool September 15, 2008 Brian Orelli	The Little Label Expansion That Couldn't Merck gets Gardasil approved to protect against other cancers, but don't expect it to increase usage very much.
The Motley Fool June 17, 2010 Brian Orelli	Merck Needs to Get Busy While waiting for the FDA to approve the expanded age range, sales of Merck's Gardasil have gone to sleep.
AskMen.com Dave Golokhov	STD Vaccine While teens and young adults account for only a quarter of the sexually active population, they are credited with half of the new STD cases per year.
The Motley Fool May 8, 2009 Brian Orelli	Glaxo Goes Head-to-Head on HPV Glaxo's data may not be enough to help Cervarix knock Merck's Gardasil from the top papillomavirus vaccine spot.
American Family Physician December 15, 2004	What You Should Know About Genital Warts An informative pamphlet on the condition, how one contracts it, treatment options and preventative advice.
Nursing October 2010 Linda Schiech	HPV-related cancer: An equal opportunity danger Although many people know that HPV infections are the leading cause of cervical cancer, they might be surprised to learn that HPV is also associated with other kinds of cancer, including cancers of the head and neck, and anal and penile cancers.
The Motley Fool March 12, 2008 Brian Lawler	A New Wave for Third Wave Molecular-diagnostics developer Third Wave Technologies might be able to help women who test positive for a common STD.
The Motley Fool June 23, 2010 Kris Eddy	Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems.
The Motley Fool April 21, 2005 Stephen D. Simpson	Merck Looks for Soft Landing Despite a tough year, the business isn't falling apart, and the pipeline has some near-term gems. This should give investors reason to expect that better things could be on the way.
BusinessWeek January 8, 2007 Arlene Weintraub	Making Her Mark At Merck Margaret McGlynn, critical to a post-Vioxx turnaround, is on a fast track.
Salon.com July 24, 2000 Arthur Allen	Foil-wrapped folly What's wrong with requiring condom wrappers to carry a warning about a cancer-causing virus? Second of two parts.
The Motley Fool July 20, 2006 Brian Lawler	MedImmune Is Easy to Resist Despite the prospects from sales of two new vaccines, it's hard to feel better about this stock.
The Motley Fool October 23, 2007 Brian Orelli	Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter.
Health October 10, 2008	Cervical Cancer FAQ Signs, symptoms, prevention, and treatments are some of the topics explained here.
The Motley Fool December 5, 2008 Brian Orelli	Good Luck in 2010, Merck It's not just one problem for Merck, but a whole series of issues that have turned the company into a heap of stale drugs.
Chemistry World February 17, 2014 Helen Bache	Small molecules stop cervical cancer virus assembling Researchers in China have disrupted the life cycle of the leading cause of cervical cancer -- the human papilloma virus -- using a macrocyclic molecule called a pillarene.
The Motley Fool July 30, 2010 Brian Orelli	It's Hard to Get Excited About 92% Revenue Growth Especially when revenue dropped on a comparable basis.
AskMen.com	STDs On The Rise Sexually spread diseases continue to rise, government health officials said. Better screening may be the reason.
BusinessWeek July 25, 2005 Catherine Arnst	O.K., Roll Up Your Sleeve New vaccines are arriving but the economics are still a challenge.
The Motley Fool June 3, 2005 Brian Gorman	Merck's New Innovation Pending FDA approval, the company's experimental shingles vaccine will probably be a steady earner. In the near term, the stock isn't going to see huge gains, but the company is here to stay and will keep innovating.
The Motley Fool February 23, 2010 Brian Orelli	The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu.
Nurse Practitioner June 2012 Kostas-Polston et al.	HPV & age-appropriate cervical cancer prevention for adolescents Adolescents have the highest rates of cervical disease as a result of initial human papillomavirus exposure and infection.
The Motley Fool December 5, 2007 Brian Orelli	Merck Stays Conservative Merck sets the bar low with its 2008 guidance. Is the company being overly cautious?
The Motley Fool December 13, 2007 Brian Orelli	Merck's Vaccination Woes Merck announces it is recalling 1.2 million doses of a vaccine that immunizes children against Hib, which causes meningitis, pneumonia, and other serious infections.
The Motley Fool February 28, 2007 Brian Lawler	Merck's Mighty Future Merck ups its 2007 financial forecast, while positive developments occur for two of its most promising new therapies.
The Motley Fool November 13, 2007 Brian Orelli	Merck: Case Closed? Now that Merck has settled its lawsuit, it can get back to business, focusing on continued growth from its cholesterol drugs, new diabetic medication, and cervical cancer vaccine. Investors, take note.
BusinessWeek July 25, 2005 Gene G. Marcial	Is Merck Rallying After That Nasty Tumble? Although most analysts who track Merck remain bearish on the beleaguered drugmaker, some upbeat investors are buying. Why? It's Vioxx market may have softened, but its new vaccines will rise to the occasion.
Chemistry World February 6, 2014 Carla Pegoraro	Catching viruses associated with cervical cancer Researchers in the UK have developed an automated bioassay that can spot the forms of the human papilloma virus most often linked with cervical cancer.
The Motley Fool September 24, 2009 Brian Orelli	Drugmakers' HIV Treatments Live On Companies that make HIV drugs could lose billions of dollars in revenue if an effective vaccine is developed. All drug-company investors need to keep an eye on up-and-coming drugs from competitors that could take market share.
The Motley Fool July 22, 2005 Karl Thiel	Cancer Drug: A Shot at Success Cancer vaccine pioneer Dendreon delivered news yesterday that its investors have been anxiously awaiting: final three-year survival data from a phase 3 study of Provenge, the company's flagship prostate cancer vaccine.